Market atlas / Inflammaging / Colchicine

Colchicine (anti-inflammatory)

repurposedsmall-moleculenlrp3-inflammasome-inhibitionmicrotubule-inhibitionanti-inflammatory● crp

Stage by geography

Same development stage across markets, but South Korea reached it about 34 years before United Kingdom.

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNJPCHSGILKR

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	approved	not dated	class Alkaloid [EPC]
UK	approved	2022-07-28	indication Adults Colchicine is indicated for the treatment of acute gout Colchicine is indicated for the prophylaxis of a gout attack during initiation of urate-lowering…
CN	approved	not dated	form Active pharmaceutical ingredient, chemical drug
JP	approved	2016-09-28	indication A drug with a new additional indication and a new dosage for the treatment of familial Mediterranean fever. [Public knowledge-based application after PAFSC's…
CH	approved	2021-06-24	indication Gouty arthritis, pericarditis, familial Mediterranean fever
SG	approved	2003-05-23	form Tablet, oral, prescription only
IL	approved	2021-06-30	indication Prevention and treatment of gout and FMF (familial mediterranean fever).
KR	approved	1988-02-29	class Gout treatment agents [MFDS 03940]

China registers · NMPA

What each NMPA register actually approved. Reference approval NMPA H53020821. Domestic generics vs imported originator.

17domestic approvals

Forms listed: 2
Product: Colchicine
Form: active pharmaceutical ingredient
Origin: China
Approved: 2026-01-14
Approval no: NMPA H53020821

Biomarker trends

no biomarker readings yet

Studies

The studies on Colchicine, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Number of atrial fibrillation (AF) recurrence	CH
Major adverse cardiovascular and limb events (MACE or MALE)	CH
Edoxaban vs. no active treatment	CH
Colchicine vs no active treatment	CH
VAS for shoulder pain	IL
Shoulder range of motion	IL
Shoulder pain and disability index	IL
Recurrence of atrial fibrillation	IL
Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.	IL
Serum colchicine level	KR

Connections

no connections yet

Trajectory

1988

MarketKR: approved-other (MFDS-approved (South Korea))

MFDS:colchicine (1988-02-29) · machine-extracted

2003

MarketSG: approved-other (HSA-registered (Singapore))

HSA:colchicine (2003-05-23) · machine-extracted

2014

ProfileColchicine (anti-inflammatory)

NCT02139046 · machine-extracted

2016

MarketJP: approved-other (PMDA-approved (Japan))

PMDA:colchicine (2016-09-28) · machine-extracted

2021

MarketCH: approved-other (Swissmedic-authorised (Switzerland))

Swissmedic:colchicin (2021-06-24) · machine-extracted

2021

MarketIL: approved-other (Israel MoH-registered)

IsraelMoH:colchicine (2021-06-30) · machine-extracted

2022

MarketUK: approved-other (MHRA-authorised (UK), per eMC SmPC)

EMC:colchicine (product 14362) · machine-extracted

2026

MarketCH: rct (clinical trials (highest phase 3))

NCT02898610 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 2))

NCT05677555 · machine-extracted

2026

MarketJP: rct (clinical trials (highest phase 2))

NCT03376698 · machine-extracted

2026

MarketKR: signal (clinical trials (highest phase ?))

NCT06543082 · machine-extracted

2026

MarketSG: rct (clinical trials (highest phase 2))

NCT00819585 · machine-extracted

2026

MarketCN: approved-other (NMPA-approved (domestic))

NMPA:NMPA H53020821 · machine-extracted

2026

MarketUS: approved-other (approved, marketed)

NDA204820 · machine-extracted

Get into the weeds: raw observations + provenance

mfds__dev_colchicine__KR  2026-07-13  kind=geography_stage  verify=M
   MFDS-approved in South Korea: Colchicine (Colchine Tab.), first approval 1988-02-29. [MFDS drug product-approval list]
   source MFDS:colchicine (1988-02-29)  https://nedrug.mfds.go.kr/pbp/CCBGA01

hsa__dev_colchicine__SG  2026-07-13  kind=geography_stage  verify=M
   HSA-registered in Singapore: COLCHICINE (COLCITEX TABLET 0.6 mg), first registration 2003-05-23. [HSA Listing of Registered Therapeutic Products]
   source HSA:colchicine (2003-05-23)  https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view

colch_facets  2026-06-29  kind=facets  verify=M
   Colchicine facets
   source NCT02139046  https://clinicaltrials.gov/study/NCT02139046

pmda__dev_colchicine__JP  2026-07-13  kind=geography_stage  verify=M
   PMDA-approved in Japan: Colchicine (Colchicine Tablets 0.5 mg "Takata" (Takata Pharmaceutical Co.,Ltd.)), first approval 2016-09-28. [PMDA List of Approved Drugs]
   source PMDA:colchicine (2016-09-28)  https://www.pmda.go.jp/files/000281190.pdf

swissmedic__dev_colchicine__CH  2026-07-13  kind=geography_stage  verify=M
   Swissmedic-authorised in Switzerland: colchicinum (COLCTAB 1 mg, tablets), first authorisation 2021-06-24. [Swissmedic list of authorised medicinal products]
   source Swissmedic:colchicin (2021-06-24)  https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/erweiterte_ham_ind.xlsx

israelmoh__dev_colchicine__IL  2026-07-13  kind=geography_stage  verify=M
   Registered in Israel (Israeli Drug Registry): COLCHICINE 500 MCG (COLCHICINE 0.5 mg ), current registration 2021-06-30. [Israel MoH Drug Registry]
   source IsraelMoH:colchicine (2021-06-30)  https://israeldrugs.health.gov.il/

colch_uk  2026-07-14  kind=geography_stage  verify=M
   UK marketing authorisation (MHRA), per the eMC SmPC: Colchicine 500 mcg Tablets [active substance: colchicine], first authorised 2022-07-28. [electronic Medicines Compendium, medicines.org.uk]
   source EMC:colchicine (product 14362)  https://www.medicines.org.uk/emc/product/14362/smpc

ctsearch__CH__dev_colchicine  2026-07-10  kind=geography_stage  verify=M
   colchicine: 8 registered trial(s) in CH, highest phase 3 [NCT02898610]
   source NCT02898610  https://clinicaltrials.gov/study/NCT02898610

ctsearch__IL__dev_colchicine  2026-07-10  kind=geography_stage  verify=M
   colchicine: 10 registered trial(s) in IL, highest phase 2 [NCT05677555]
   source NCT05677555  https://clinicaltrials.gov/study/NCT05677555

ctsearch__JP__dev_colchicine  2026-07-10  kind=geography_stage  verify=M
   colchicine: 2 registered trial(s) in JP, highest phase 2 [NCT03376698]
   source NCT03376698  https://clinicaltrials.gov/study/NCT03376698

ctsearch__KR__dev_colchicine  2026-07-10  kind=geography_stage  verify=M
   colchicine: 4 registered trial(s) in KR, highest phase ? [NCT06543082]
   source NCT06543082  https://clinicaltrials.gov/study/NCT06543082

ctsearch__SG__dev_colchicine  2026-07-10  kind=geography_stage  verify=M
   colchicine: 2 registered trial(s) in SG, highest phase 2 [NCT00819585]
   source NCT00819585  https://clinicaltrials.gov/study/NCT00819585

nmpa__dev_colchicine__CN  2026-07-13  kind=geography_stage  verify=M
   NMPA-approved in China (colchicine): 17 domestic approval(s) (e.g. Colchicine, China). Reference NMPA H53020821.
   source NMPA:NMPA H53020821  https://www.nmpa.gov.cn/datasearch/home-index.html

openfda__NDA204820__US  2026-07-13  kind=geography_stage  verify=M
   FDA-approved in the US (COLCHICINE); approved, marketed [NDA204820]
   source NDA204820  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA204820